Methodology for the Development of Clinical Practice Guidelines for Chinese Patent Medicine （Part 8）： Quality Evaluation with AGREE Ⅱ and RIGHT
10.13288/j.11-2166/r.2024.02.012
- VernacularTitle:中成药临床实践指南制定方法（八）
- Author:
Fuqiang ZHANG
1
;
Ziteng HU
1
;
Yujing ZHANG
1
;
Lijiao YAN
1
;
Juyi WANG
2
;
Cehan ZHANG
3
;
Jiaqi CHEN
4
;
Mengyi WANG
5
;
Shuoming LIU
6
;
Xinyi XIE
1
;
Ning LIANG
1
;
Nannan SHI
1
;
Yanping WANG
1
Author Information
1. Institute of Basic Research in Clinical Medicine， China Academy of Chinese Medical Sciences， Beijing， 100700
2. Institute for History of Medicine and Medical Literature， China Academy of Chinese Medical Sciences
3. Shanghai University of Traditional Chinese Medicine
4. School of Acupuncture， Moxibustion and Tuina， Shandong University of Traditional Chinese Medicine
5. Institute of Health Sciences， China Medical University
6. Tianjin University of Traditional Chinese Medicine
- Publication Type:Journal Article
- Keywords:
clinical practice guidelines;
Chinese patent medicines;
expert consensus;
quality evaluation;
AGREE Ⅱ;
RIGHT
- From:
Journal of Traditional Chinese Medicine
2024;65(2):185-191
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo evaluate the methodological and reporting quality of clinical practice guidelines for Chinese patent medicine （CPM） with internationally recognized tools the appraisal of guidelines for research and evaluation （AGEREE） Ⅱ and reporting items for practice guidelines in healthcare （RIGHT）， thereby providing refe-rence for the clinical application and future development of CPM guidelines. MethodsDatabases including CNKI， VIP， Wanfang and Sinomed were searched for CPM guidelines， as well as medlive.cn， websites of China Association of Chinese Medicine and Chinese Medical Association， and reference lists of the included papers. The quality of the guidelines was evaluated using the AGREE Ⅱand RIGHT tools， and consistency tests were performed using Interclass Correlation Coefficient， and descriptive analysis and chi-square test were used to analyze the reporting rate for each domain and the average score for each item. ResultsFinally， 140 CPM guidelines were included， of which 51 were disease-oriented and 89 were drug-oriented， all of which were issued by China. For 51 disease-oriented CPM guidelines， the highest average score of all six AGREE Ⅱ domains was 73.32% for clarity， and the lowest was 26.80% for application； for 89 drug-oriented CPM guidelines， the highest average score was 55.62% for scope and purpose， and the lowest was 31.32% for rigour of development. In terms of the seven domains of the RIGHT checklist， the highest reporting rate was 68.26% for background， and lowest was 27.45% for other areas regarding the disease-oriented CPM guidelines； the highest reporting rate was 61.31% for background， and the lowest was 4.49% for other areas regarding drug-oriented CPM guidelines. The average reporting rate was higher for disease-oriented than drug-oriented CPM guidelines in three domains of AGREE Ⅱ （rigour of development， clarity of presentation， editorial independence）， as well as four domains of RIGHT checklist （basic information， evidence， funding and declaration and management of interests， and other areas）. ConclusionThe overall methodology and reporting quality of the current CPM guidelines still need to be improved. It is recommended that future guideline development teams should strictly refer to the AGREE Ⅱ and RIGHT checklist， and take into account of the characteristics of CPM guidelines and relevant methodo-logical suggestions in the development and reporting of CPM guidelines， thereby guiding the clinical use of CPM in a better way.
